CN101707888B - 用7-乙基-10-羟基喜树碱的多臂聚合物缀合物治疗非霍奇金氏淋巴瘤 - Google Patents
用7-乙基-10-羟基喜树碱的多臂聚合物缀合物治疗非霍奇金氏淋巴瘤 Download PDFInfo
- Publication number
- CN101707888B CN101707888B CN2007800343014A CN200780034301A CN101707888B CN 101707888 B CN101707888 B CN 101707888B CN 2007800343014 A CN2007800343014 A CN 2007800343014A CN 200780034301 A CN200780034301 A CN 200780034301A CN 101707888 B CN101707888 B CN 101707888B
- Authority
- CN
- China
- Prior art keywords
- compound
- agent
- purposes
- treatment
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84493806P | 2006-09-15 | 2006-09-15 | |
US60/844,938 | 2006-09-15 | ||
US86451606P | 2006-11-06 | 2006-11-06 | |
US60/864,516 | 2006-11-06 | ||
US11/704,607 US7462627B2 (en) | 2006-02-09 | 2007-02-09 | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
US11/704,607 | 2007-02-09 | ||
PCT/US2007/076241 WO2008033643A2 (en) | 2006-09-15 | 2007-08-17 | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101707888A CN101707888A (zh) | 2010-05-12 |
CN101707888B true CN101707888B (zh) | 2013-05-15 |
Family
ID=39184444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007800343014A Expired - Fee Related CN101707888B (zh) | 2006-09-15 | 2007-08-17 | 用7-乙基-10-羟基喜树碱的多臂聚合物缀合物治疗非霍奇金氏淋巴瘤 |
Country Status (11)
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
US7671067B2 (en) * | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
RU2009133793A (ru) * | 2007-02-09 | 2011-03-20 | Энзон Фармасьютикалз, Инк. (Us) | Лечение резистентных или невосприимчивых форм рака конъюгатами 7-этил-10-гидроксикампотецина с множеством ответвлений цепи |
CA2732508C (en) | 2008-08-11 | 2016-03-15 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
WO2010025337A1 (en) * | 2008-08-29 | 2010-03-04 | Enzon Pharmaceuticals, Inc. | Method of treating ras associated cancer |
ES2744975T3 (es) | 2008-09-23 | 2020-02-27 | Nektar Therapeutics | Método de dosificación metronómica con profármacos de camptotecina (p. ej. PEG-Irinotecán) |
AU2009307922A1 (en) * | 2008-10-21 | 2010-04-29 | Enzon Pharmaceuticals, Inc. | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
EP2427176A4 (en) * | 2009-05-04 | 2014-03-19 | Intezyne Technologies Inc | POLYMERIC MICELLES CONTAINING SN-38 FOR USE IN THE TREATMENT OF CANCER |
BR112012001395A2 (pt) * | 2009-07-22 | 2019-09-24 | Enzon Pharmaceuticals Inc | metodo para tratar um câncer her2 positivo em um mamifero metodo para aumentar os efetivos de antagonistas do receptor her2 em um mamifero apresentando um cancêr her2 positivo metodo para inibir o crescimento ou proliferação de células her2 positivas em um mamifero |
US9226969B2 (en) | 2009-11-18 | 2016-01-05 | Nektar Therapeutics | Salt form of a multi-arm polymer-drug conjugate |
US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
WO2012088422A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
ES2759905T3 (es) | 2013-10-04 | 2020-05-12 | Prolynx Llc | Conjugados de liberación lenta de SN-38 |
CN104650342B (zh) * | 2013-11-18 | 2018-07-10 | 江苏豪森药业集团有限公司 | 多支链聚合药物前体及其应用 |
CN108727582B (zh) * | 2017-04-21 | 2021-11-05 | 博瑞生物医药(苏州)股份有限公司 | 靶向抗癌偶联物 |
US20200360545A1 (en) | 2018-01-12 | 2020-11-19 | Prolynx Llc | Protocol for minimizing toxicity of combination dosages and imaging agent for verification |
CN110577550A (zh) * | 2018-06-08 | 2019-12-17 | 遵义医学院 | 喜树碱-甘氨酸-去甲斑蝥素结合物及其应用 |
WO2022035843A1 (en) * | 2020-08-12 | 2022-02-17 | Nanomedicine Innovation Center, Llc | Topoisomerase inhibitors |
CN116406301A (zh) | 2020-09-28 | 2023-07-07 | 生物医药研究基金会机构(Irb巴塞罗那) | 可用于治疗癌症的sn38肽缀合物 |
WO2023095741A1 (ja) * | 2021-11-25 | 2023-06-01 | 日油株式会社 | 医療用4分岐型水溶性ポリマー |
WO2023186822A1 (en) | 2022-03-28 | 2023-10-05 | Hospital Sant Joan De Deu | Peptidic water-soluble delivery system of anticancer drugs |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001068066A2 (en) * | 2000-03-17 | 2001-09-20 | Aventis Pharma S.A. | A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer |
WO2007092646A2 (en) * | 2006-02-09 | 2007-08-16 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4473692A (en) * | 1981-09-04 | 1984-09-25 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
US4943579A (en) * | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
WO1993024476A1 (en) * | 1992-06-04 | 1993-12-09 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
US5614549A (en) * | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5965566A (en) * | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5840900A (en) * | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5605976A (en) * | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5730990A (en) * | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
US5736156A (en) * | 1995-03-22 | 1998-04-07 | The Ohio State University | Liposomal anf micellular stabilization of camptothecin drugs |
IL117684A (en) * | 1995-04-07 | 2002-02-10 | Pharmacia & Upjohn Inc | Intermediates and Process for Production of History of Kempotocin (CPT-11) and Related Compounds |
US5726181A (en) * | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
SG50747A1 (en) | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
JPH10168373A (ja) * | 1996-12-12 | 1998-06-23 | Fuji Xerox Co Ltd | インクジェット記録用インク及びそれを用いる記録方法 |
JP3855344B2 (ja) * | 1997-02-19 | 2006-12-06 | 日本油脂株式会社 | ポリオキシアルキレンカルボン酸の製造方法 |
US6011042A (en) * | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
US6111107A (en) * | 1997-11-20 | 2000-08-29 | Enzon, Inc. | High yield method for stereoselective acylation of tertiary alcohols |
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
US6153655A (en) * | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US6897200B1 (en) * | 1998-10-14 | 2005-05-24 | University Of Kentucky Research Foundation | Oligonucleotide delivery systems for camptothecins |
JP2002534098A (ja) * | 1999-01-06 | 2002-10-15 | コーネル リサーチ ファンデーション インク. | ゲノムシークエンシングにおける単一ヌクレオチドの多型の加速度的な同定およびクローンの整列化 |
US6723338B1 (en) * | 1999-04-01 | 2004-04-20 | Inex Pharmaceuticals Corporation | Compositions and methods for treating lymphoma |
US6316462B1 (en) * | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
AU772074B2 (en) | 1999-04-28 | 2004-04-08 | Vectramed, Inc. | Enzymatically activated polymeric drug conjugates |
AU4564200A (en) * | 1999-04-29 | 2000-11-17 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
EP1466627A1 (en) * | 1999-10-12 | 2004-10-13 | Cell Therapeutics, Inc. | Polyglutamate camptothecin conjugates |
DK1259562T3 (da) * | 1999-12-22 | 2006-04-18 | Nektar Therapeutics Al Corp | Sterisk hindrede derivater af vandoplöselige polymerer |
US20040009229A1 (en) * | 2000-01-05 | 2004-01-15 | Unger Evan Charles | Stabilized nanoparticle formulations of camptotheca derivatives |
WO2001051494A1 (en) * | 2000-01-12 | 2001-07-19 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
AU2001257577A1 (en) * | 2000-02-28 | 2001-09-03 | Shearwater Corporation | Water-soluble polymer conjugates of artelinic acid |
BR0109272A (pt) * | 2000-03-17 | 2004-06-29 | Cell Therapeutics Inc | Agentes conjugados terapêuticos de ácido poliglutâmico, métodos para suas preparações e usos |
US6756037B2 (en) * | 2000-03-31 | 2004-06-29 | Enzon, Inc. | Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups |
US6629995B1 (en) | 2000-03-31 | 2003-10-07 | Super Gen, Inc. | Camptothecin conjugates |
US20020182172A1 (en) * | 2000-11-30 | 2002-12-05 | Shearwater Corporation | Water-soluble polymer conjugates of triazine derivatives |
US20020123401A1 (en) * | 2001-03-02 | 2002-09-05 | Henry Rassem Ragheb | Combination starter-generator |
US20020182272A1 (en) * | 2001-05-30 | 2002-12-05 | Bruce Halstead | Methods of treatment of HIV-associated conditions |
JP4123856B2 (ja) * | 2001-07-31 | 2008-07-23 | 日油株式会社 | 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法 |
WO2003033525A1 (en) | 2001-10-12 | 2003-04-24 | Debio Recherche Pharmacuetique S.A. | Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament |
CA2463580A1 (en) | 2001-10-29 | 2003-05-08 | Michael David Bentley | Polymer conjugates of protein kinase c inhibitors |
ATE359829T1 (de) | 2001-10-30 | 2007-05-15 | Nektar Therapeutics Al Corp | Wasserlösliche polymerkonjugate von retinoesäure |
US6608076B1 (en) * | 2002-05-16 | 2003-08-19 | Enzon, Inc. | Camptothecin derivatives and polymeric conjugates thereof |
BR0312685A (pt) * | 2002-06-06 | 2005-09-06 | Univ Washington | Métodos de utilização de compostos do tipo artemisinina para prevenir ou retardar o aparecimento de cancêr |
CA2497792C (en) * | 2002-09-06 | 2014-08-05 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
US6649778B1 (en) * | 2002-09-20 | 2003-11-18 | Enzon, Inc. | Methods of preparing amino acid taxane derivatives and polymer conjugates containing the same |
US7879868B2 (en) * | 2002-10-11 | 2011-02-01 | Novartis Ag | Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents |
KR20140067141A (ko) * | 2002-12-16 | 2014-06-03 | 글로브이뮨 | 면역 요법으로서의 효모계 백신 |
EP1578843B1 (en) | 2002-12-31 | 2008-07-09 | Nektar Therapeutics Al, Corporation | Methods for the formation of hydrogels using thiosulfonate compositions and uses thereof |
US20040247624A1 (en) * | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
US8394365B2 (en) * | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
KR20120073370A (ko) * | 2003-09-17 | 2012-07-04 | 넥타르 테라퓨틱스 | 다분지형 고분자 전구약물 |
US20050214250A1 (en) | 2003-11-06 | 2005-09-29 | Harris J M | Method of preparing carboxylic acid functionalized polymers |
CN101132812A (zh) * | 2004-03-15 | 2008-02-27 | 阿拉巴马耐科塔医药公司 | Hiv进入抑制剂的聚合物基组合物和结合物 |
CA2561111A1 (en) * | 2004-03-26 | 2005-10-13 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
US7989554B2 (en) | 2006-01-10 | 2011-08-02 | Enzon Pharmaceuticals, Inc. | Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid |
US7671067B2 (en) * | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
RU2009133793A (ru) * | 2007-02-09 | 2011-03-20 | Энзон Фармасьютикалз, Инк. (Us) | Лечение резистентных или невосприимчивых форм рака конъюгатами 7-этил-10-гидроксикампотецина с множеством ответвлений цепи |
-
2007
- 2007-02-09 US US11/704,607 patent/US7462627B2/en not_active Expired - Fee Related
- 2007-08-17 KR KR1020097005140A patent/KR20090059117A/ko not_active Application Discontinuation
- 2007-08-17 MX MX2009002853A patent/MX2009002853A/es not_active Application Discontinuation
- 2007-08-17 CN CN2007800343014A patent/CN101707888B/zh not_active Expired - Fee Related
- 2007-08-17 CA CA002662920A patent/CA2662920A1/en not_active Abandoned
- 2007-08-17 AU AU2007297042A patent/AU2007297042B2/en not_active Ceased
- 2007-08-17 EP EP07814225A patent/EP2073809A4/en not_active Withdrawn
- 2007-08-17 BR BRPI0716807-1A patent/BRPI0716807A2/pt not_active IP Right Cessation
- 2007-08-17 WO PCT/US2007/076241 patent/WO2008033643A2/en active Application Filing
- 2007-08-17 KR KR1020147035602A patent/KR20150005721A/ko not_active Application Discontinuation
- 2007-08-17 JP JP2009528374A patent/JP2010503691A/ja active Pending
-
2008
- 2008-11-20 US US12/274,474 patent/US7723351B2/en not_active Expired - Fee Related
-
2009
- 2009-02-19 IL IL197122A patent/IL197122A0/en unknown
-
2010
- 2010-04-19 US US12/762,434 patent/US8299089B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001068066A2 (en) * | 2000-03-17 | 2001-09-20 | Aventis Pharma S.A. | A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer |
WO2007092646A2 (en) * | 2006-02-09 | 2007-08-16 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
Non-Patent Citations (1)
Title |
---|
王毓銮,米振国.《非霍奇淋巴瘤的化学治疗》.《现代非霍奇金淋巴瘤学》.2003, * |
Also Published As
Publication number | Publication date |
---|---|
US8299089B2 (en) | 2012-10-30 |
IL197122A0 (en) | 2009-11-18 |
US20090074706A1 (en) | 2009-03-19 |
EP2073809A4 (en) | 2011-04-13 |
WO2008033643A2 (en) | 2008-03-20 |
JP2010503691A (ja) | 2010-02-04 |
EP2073809A2 (en) | 2009-07-01 |
AU2007297042A1 (en) | 2008-03-20 |
WO2008033643A3 (en) | 2008-12-11 |
CN101707888A (zh) | 2010-05-12 |
US7723351B2 (en) | 2010-05-25 |
US7462627B2 (en) | 2008-12-09 |
BRPI0716807A2 (pt) | 2013-11-05 |
CA2662920A1 (en) | 2008-03-20 |
MX2009002853A (es) | 2009-03-27 |
KR20150005721A (ko) | 2015-01-14 |
KR20090059117A (ko) | 2009-06-10 |
US20070197575A1 (en) | 2007-08-23 |
US20100204261A1 (en) | 2010-08-12 |
AU2007297042B2 (en) | 2013-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101707888B (zh) | 用7-乙基-10-羟基喜树碱的多臂聚合物缀合物治疗非霍奇金氏淋巴瘤 | |
CN101420963B (zh) | 用于治疗乳腺癌、结肠直肠癌、胰腺癌、卵巢癌和肺癌的7-乙基-10-羟基喜树碱的多臂聚合轭合物 | |
KR101057102B1 (ko) | 캄프토테신의 고분자량 유도체 | |
JP5008783B2 (ja) | 高分子量のポリマーを基剤とするプロドラッグ | |
CA2208841C (en) | High molecular weight polymer-based prodrugs | |
EP2341774B1 (en) | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin | |
US8048891B2 (en) | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin | |
JP7376694B2 (ja) | 再生可能資源に由来するポリマーおよび組成物 | |
JP2019094260A (ja) | 癌疾患治療用ナノ粒子化製剤 | |
RU2697551C2 (ru) | Новые производные peg | |
CN110418653B (zh) | 一种果胶-阿霉素轭合物及其制备方法和用途 | |
CN116133693A (zh) | 载药的大分子及其制备方法 | |
CN105777769A (zh) | 一种7-乙基-10-羟基喜树碱的衍生物及其制备方法与应用 | |
JP2009539879A (ja) | インデノイソキノリン放出性ポリマー複合体 | |
JP2019515025A (ja) | トポイソメラーゼ毒 | |
JP2021147340A (ja) | 化合物、そのナノ粒子及び癌疾患の治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130515 Termination date: 20140817 |
|
EXPY | Termination of patent right or utility model |